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AbstrACt
Introduction Natural orifice transluminal endoscopic 
surgery (NOTES) uses natural orifices to access 
the cavities of the human body to perform surgical 
interventions. NOTES limits the magnitude of surgical 
trauma and potentially reduces postoperative pain. 
Our group published a protocol on a randomised 
study comparing transvaginal NOTES (vNOTES) versus 
laparoscopy for hysterectomy (HALON). We simultaneously 
designed a similar randomised controlled trial (RCT) 
comparing vNOTES with laparoscopy for adnexectomy. To 
the best of our knowledge, this is the first RCT comparing 
vNOTES with laparoscopy for adnexal surgery.
Methods and analysis The methodology of the Notes 
Adnexectomy for Benign Indication versus Laparoscopic 
Excision (NOTABLE) study is similar to that of the HALON 
trial. Women aged 18–70 years with an indication for benign 
adnexal surgery will be eligible. We will use stratification 
according to adnexal size. Entrants will be randomised to the 
laparoscopic treatment (control) or vNOTES (intervention). 
Participants will be evaluated on days 0–7 and at 3 and 
6 months. The primary outcome will be the proportion of 
women successfully treated by removing an adnexa by the 
allocated technique without conversion. We will collect the 
following data (secondary outcomes): proportion of women 
hospitalised on the day of surgery, postoperative pain scores 
measured two times per day from day 1 to 7, total dosage 
of pain killers used from day 1 to 7, hospital readmission 
during the first 6 weeks, dyspareunia and sexual well-being 
at baseline, 3 and 6 months using a validated questionnaire 
(Short Sexual Functioning Scale), health-related quality 
of life at baseline, 3 and 6 months after surgery using a 
validated questionnaire (EQ-5D-3L), duration of surgical 
intervention, infection or other surgical complications and 
direct costs up to 6 weeks following surgery. For the primary 
outcome measure, a one-sided 95% CI of the difference in 
the proportions of women with a successful removal of the 
uterus by the randomised technique will be estimated. Non-
inferiority will be concluded when 15% lies above the upper 
limit of this 95% CI.
Ethics and dissemination The study was approved on 
1 December 2015 by the EthicsCommitteeof the Imelda 
Hospital (registration no: 689), Bonheiden, Belgium. We 
aim to present the final results of the NOTABLE trial in 
peer-reviewed journals and at scientific meetings within 4 
years after the start of the recruitment.
trial registration number NCT02630329.
bACkground 
Laparoscopic surgery has reduced surgical 
morbidity and mortality. ‘Minimally invasive 
surgery’ has moved even further forward with 
newer techniques such as single incision lapa-
roscopic surgery and natural orifice translu-
minal endoscopy (NOTES) with or without 
robot assistance.
The NOTES technique uses any natural 
orifice (mouth, vagina, urethra or rectum) as 
a possible access route facilitating a surgical 
intervention in a cavity of the human body. 
Clinical researchers at Johns Hopkins Univer-
sity first reported its use in 2004 in a preclin-
ical trial using an animal model.1 Ever since 
the clinical application of NOTES has been 
strengths and limitations of this study
 ► This study is a randomised controlled trial.
 ► The patients, the outcome assessors and the 
personnel are blinded in this trial.
 ► This is a single-centre study.
 ► The generalisability of this study to a ‘real-life’ 
setting is limited due to the experimental setting of 
the study.
 ► The use of non-therapeutic incisions for blinding 
may confound the outcome pain.
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reported in many surgical procedures in ways that seem 
to defy human imagination, appendectomy and chole-
cystectomy have been performed using the mouth and 
the stomach as the access route.2 3 The technique seems 
feasible and safe in the hands of experienced surgeons 
beyond their surgical learning curve. Observational 
evidence (mostly case reports) has reported, moreover, 
that NOTES may cause less postoperative pain, a shorter 
length of hospital stay, less complications and last but 
not least, for female patients, improved cosmetic results. 
The feasibility of scar-free surgery in combination with 
reduced wound (trocar) complications may be tempting 
for patients and their care providers. This may be a strong 
facilitator for the widespread implementation of this new 
surgical approach.
NOTES has gained popularity among general surgeons, 
urologists and gastroenterologists over the past few years, 
and its feasibility and safety in these domains have been 
reported.4 Although NOTES may be performed using 
various entries including the stomach, oesophagus, 
bladder and rectum, the majority of NOTES procedures 
in women have been performed through the vagina.5 
This is not surprising because the colpotomy technique 
has been used widely in vaginal prolapse surgery and for 
benign adnexal surgery involving the extraction of large 
specimens. Its use has been reported as a safe access.6 7 Two 
variants of NOTES have been described in the present 
literature. Hybrid NOTES combines the access through 
the vagina with transabdominal assistance; pure NOTES 
refers to procedures that involve only transluminal access.
The removal of one or both adnexa using a transvag-
inal NOTES (vNOTES) approach was described for 
the first time by Lee and coworkers in 2012.8 vNOTES 
adnexectomy for benign pathology was introduced at 
our department by the first author (JFB) in 2013. Our 
group published three small case series on adnexal 
removal (n=20),9 salpingectomy (n=5)10 and hysterec-
tomy (n=10)11 by vNOTES during the period between 
November 2013 and February 2015. We also published the 
protocol of the laparoscopy for hysterectomy (HALON) 
study randomly comparing NOTES and laparoscopy for 
doing hysterectomy in women with benign gynaecolog-
ical disease.12 The recruitment of the HALON study was 
finished recently (24 February 2017). The final data anal-
ysis of the HALON study is foreseen for September 2017.
objectives and hypotheses
We started our research by doing a systematic review (SR) 
of the literature. We searched MEDLINE, EMBASE and 
the Cochrane Library from inception to 1 August 2015 
using a combination of MeSH terms and key words for 
‘colpotomy’ and ‘adnexal diseases’ or ‘adnexal mass’. We 
aim to publish the results of this systematic search of the 
literature and a critical appraisal of the retrieved evidence 
in a separate SR: we will adhere to the Preferred Reporting 
Items for Systematic Review and Meta-Analysis Protocols 
guidelines13 for the protocol of this SR. The protocol of 
the SR has been registered in the International Prospective 
Register of Systematic Reviews (PROSPERO) at the 
Centre for Reviews and Dissemination (CRD), Univer-
sity of York, UK14 as CRD42016033670. To the best of our 
knowledge, no randomised controlled studies comparing 
vNOTES with the transabdominal laparoscopic approach 
for removal of one or both adnexa have been published 
in the literature. The main objective of the NOTABLE 
study is to study the effectiveness of vNOTES for success-
fully removing one or both adnexa for benign gynaeco-
logical disease using the classical laparoscopic approach 
as the established effective technique. The rationale and 
the objectives of NOTABLE are in accordance with the 
principles outlined by the Idea Development Exploration 
Assessment Long term study (IDEAL) collaboration.15–17
Our primary study hypothesis is that vNOTES is not 
inferior to transabdominal laparoscopy for removing one 
or both adnexa for a benign gynaecological indication 
without having to convert to another technique. vNOTES 
may offer several advantages including the avoidance of 
abdominal scars, less need for hospital admission and 
possibly less postoperative pain.
MEthods
trial design and study analysis
The NOTABLE study should be considered as a pilot 
study. It is a single-centre parallel-group double-blinded 
(patient and outcome assessor) randomised trial 
conducted at the Department of Gynaecology of the 
Imelda Hospital in Bonheiden. This is a general hospital 
in Belgium serving an estimated population of 150 000 
people. All women aged 18–70 years bound to undergo 
removal of one or both adnexa for benign gynaecological 
disease will be informed about the NOTABLE study, and 
they will be invited to participate in the study, if eligible. 
The baseline characteristics of eligible women not wishing 
to give informed consent for participating in the study will 
be recorded as well as the reason for declining to partici-
pate. All surgical procedures (vNOTES and laparoscopy) 
will be done by one surgeon (JFB) who is equally skilled 
in both techniques. The surgeon has been using the 
vNOTES approach for various interventions (salpingec-
tomy for Extra-Uterine Gravidity (EUG), adnexectomy 
and hysterectomy) since November 2013. JFB is also the 
surgeon performing the hysterectomies in the HALON 
trial. The surgeon cannot be blinded, but the allocated 
treatment will be concealed. We will use a non-inferi-
ority study design to test the effectiveness of vNOTES 
compared with laparoscopy. The protocol adheres to the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials standards (http://www. spirit- statement. 
org/). The study protocol of the NOTABLE trial is very 
similar to that of the earlier published HALON study.12
study dates
The first patient was included on 15 January 2016. On 
22 May 2017, 38 of the targeted 70 participants were 
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recruited. Anticipated date of study completion is esti-
mated in May 2018.
Participants
NOTABLE will recruit eligible women aged 18–70 years, 
regardless of parity, who need the removal of one or both 
adnexa for a benign adnexal disease and who provide 
informed consent prior to surgery.
Exclusion criteria are as follows:
 ► history of rectal surgery
 ► suspected rectovaginal endometriosis
 ► suspected malignancy
 ► history of pelvic inflammatory disease
 ► active lower genital tract infection
 ► virginity
 ► pregnancy
 ► failure to provide written informed consent.
Intervention, procedures and standard care
On the day of the surgery, all patients are admitted to the 
day care unit. A nurse administers clindamycin vaginal 
cream on admission.
Under general anaesthesia, the patient is positioned in 
a vacuum mattress in the classical lithotomy. An alcoholic 
Betadine solution is used for disinfection of the vagina, 
vulva and abdomen before draping. A Foley catheter is 
inserted into the bladder. In accordance with hospital 
protocol, the anaesthesiologist will administer cefazolin 
2 g and metronidazole 1.5 g intravenous prior to incision 
for prophylaxis against infection to all women of both 
treatment arms. In both groups, a 30° rigid endoscope 
is used.
Control group: laparoscopic technique
The surgeon will start the procedure by making a small 
vertical intraumbilical skin incision. A Veress needle is 
introduced into the peritoneal cavity; the tip position 
is checked with a Semm test before insufflating carbon 
dioxide (CO2) until a maximal intraperitoneal pressure 
of 15 mm Hg. A 10 mm trocar is inserted through the 
umbilicus after removal of the Veress needle. An optic is 
inserted to inspect the peritoneal cavity. The operating 
table is tilted in the Trendelenburg position. Two 5 mm 
trocars are placed under direct vision in the suprapubic 
region and in the left iliac fossa lateral of the epigastric 
vessels. The small intestine is lifted out of the pelvis.
The ureter is identified, but no retroperitoneal dissec-
tion is performed unless indicated. The proximal end of 
the Fallopian tube is coagulated at its origin in the uterus 
using a reusable bipolar grasping forceps before being 
cut with cold microscissors. The ovarian and infundibu-
lopelvic ligament are coagulated and cut. After resection, 
the adnexa is placed in an endobag (Memobag; Teleflex, 
Wayne, Pennsylvania, USA). When indicated, the same 
procedure is repeated for the contralateral side.
After confirmation of haemostasis, the peritoneal cavity 
is rinsed. No drains are left in the peritoneal cavity unless 
necessary, for example, problematic haemostasis. The 
5 mm trocars are be removed under direct vision. The 
purse string of the endobag is pulled through the 10 mm 
trocar on removal of the optic. The umbilical incision 
is extended vertically in caudal direction, but not more 
than 2.5 cm. The fascia and peritoneum are opened, and 
the proximal end of the endobag is pulled through the 
incision without causing any rupture if possible. If not 
possible, the endobag will be opened, and the content 
of the cyst will be aspirated to reduce the volume of the 
adnexa. The aspirated fluid will be sent for cytological 
evaluation. The endobag will then be removed with the 
adnexa inside it.
The fascia is closed using a Vicryl-1 running suture. The 
umbilicus and other incisions are disinfected with Beta-
dine solution. All skin incisions are closed with a Monocryl 
3/0 intradermal suture and approximated using steris-
trips. The wound sites are covered with a wound dressing. 
A vaginal plug (Betadine gauze 10 cm×5 m) is inserted 
into the vagina. After 3 hours, the Foley catheter and the 
vaginal plug are removed.
Intervention group: vNOTES
The surgeon makes three non-therapeutic superficial 
skin incisions on exactly the same location as in the clas-
sical laparoscopic approach in all women allocated to 
the vNOTES group to blind study participants and the 
outcome assessor to the allocated technique. A 2.5 cm 
posterior colpotomy is made using a cold knife. The 
pouch of Douglas is opened using scissors. A Gelpoint 
Mini (Applied Medical), used as vNOTES port, is inserted 
into the pouch of Douglas. CO2 is insufflated until a 
maximal intraperitoneal pressure of 15 mm Hg. An optic 
is inserted to inspect the peritoneal cavity. The operating 
table is tilted in the Trendelenburg position. The small 
intestine is lifted out of the pelvis.
The ureter is identified, but no retroperitoneal dissec-
tion is performed unless indicated. The proximal end 
of the Fallopian tube is coagulated at its origin into the 
uterus using a reusable bipolar grasping forceps and cut 
using microscissors. The ovarian and infundibulopelvic 
ligament are coagulated and cut. The adnexa is removed. 
When indicated, the procedure is repeated for the contra-
lateral side. After confirmation of haemostasis, the perito-
neal cavity is rinsed.
Small benign-looking adnexa is removed directly 
through the wound protector part of the vNOTES port. 
Large adnexa or adnexa that appears macroscopically 
suspicious is placed in an endobag (Memobag; Teleflex). 
The purse string of the endobag is pulled through the 
wound protector, and the purse string released. The 
content of the cyst is aspirated to reduce the volume 
of the adnexa. The endobag is then removed with the 
adnexa inside it. The vNOTES port is removed.
The colpotomy is closed using three interrupted 
figure-of-eight Vicryl 2/0 sutures. A vaginal plug (Beta-
dine gauze 10 cm×5 m) is inserted into the vagina. After 
3 hours, the Foley catheter and the vaginal plug are 
removed.
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In the majority of patients, it is feasible to perform a 
successful vNOTES or laparoscopic adnexectomy. Women 
in whom the intended approach has to be abandoned 
for an alternative intervention will not be excluded or 
withdrawn from the NOTABLE trial but will be followed 
up further. It is anticipated that most included patients 
with a normal cancer antigen 125 value, and benign 
features of the ovary on ultrasound will not require other 
interventions besides the removal of the adnexa. If the 
responsible clinician judges that additional treatment is 
necessary at the time of the surgery or afterwards, this 
will be recorded and the patient will not be withdrawn 
from the study. However, if there is a preoperative indi-
cation for additional surgery during the same procedure, 
these patients will be excluded from recruitment to the 
NOTABLE trial.
The anaesthesiologists involved in the clinical trial have 
developed a standardised protocol to insure that the pain 
management is identical for both groups. The outcome 
assessor (JJAB) and the patient are both blinded to the 
surgical approach used. The patient makes the decision 
to be discharged from the day care unit on the evening of 
the procedure or to be admitted to an in-hospital nursing 
ward for the night. The outcome assessor can only over-
rule the patient’s decision in the interest of her health, 
for example, when surgical complications were recorded 
in the surgical report or when vital parameters indicate a 
life-threatening condition. Before discharge, all patients 
are given a standard list of instructions to avoid physical 
work, exercise and sexual intercourse for 4 weeks after the 
intervention.
All participants, regardless of being at home or in 
hospital, are requested to use a Visual Analogue Scale 
(VAS) two times per day to measure postoperative pain 
from day 1 to day 7 following surgery. Adequate instruc-
tions on how to use the VAS measuring tool are given on 
an individual basis by a dedicated nurse of the day care 
unit. One measurement is made in the evening before 
going to bed after physical activity (active), and another 
is made in the morning after bed rest at night (rest). All 
patients are asked to note the name, dosage and route of 
administration of any analgesic drug taken from day 1 to 
7 in a pain log book.
outcome measure
We searched the COMET18 database for a core outcome 
set for adnexectomy (general settings) in gynaecology 
(health area-disease category) in women (target popula-
tion: sex) aged 18 to 70 years (target population: age): 
no core outcome set relevant to laparoscopic removal of 
adnexa was identified.19
Primary outcome measure
The proportion of women successfully treated by 
removing one or both adnexa without spill by the allo-
cated technique as randomised will be measured as the 
primary outcome of effectiveness.
Secondary outcome measures
The secondary outcomes are as follows:
 ► The proportion of women hospitalised on the day of 
surgery based on their own preference.
 ► Postoperative pain scores measured using VAS20 two 
times per day from day 1 to 7.
 ► The total dosage of pain killers taken during the first 
week following surgery.
 ► Postoperative infection defined by lower abdominal 
pain with fever >38°C and positive clinical signs or 
laboratory findings detected during the first 6 weeks 
of surgery.
 ► Intraoperative or postoperative complications classi-
fied according to the Clavien-Dindo classification21 
detected during the first 6 weeks of surgery.
 ► Readmission to hospital during the first 6 weeks of 
surgery.
 ► Occurrence and severity of pain on sexual intercourse 
self-reported by the study participants at baseline, 3 
and 6 months by using a simple questionnaire and 
VAS.
 ► Sexual well-being at baseline, 3 and 6 months by 
self-reporting the Short Sexual Functioning Scale 
(SSFS).22
 ► Health-related quality of life (QoL) at baseline, 3 and 
6 months after surgery by self-reporting using a vali-
dated questionnaire (EQ-5D-3L).
 ► The duration of the surgical intervention measured in 
minutes from the insertion of the bladder catheter to 
the end of vaginal/abdominal wound closure.
 ► Direct costs for both techniques up to 6 weeks 
following surgery.
The SSFS and the EQ-5D-3L questionnaires were vali-
dated in Dutch and presented to the participants in their 
mother tongue.
randomisation and blinding
Participants will be randomly allocated to one of both 
treatment arms (vNOTES vs laparoscopy). We will use 
a computer-generated randomisation schedule gener-
ated by the management assistant of our department. 
We will use a stratification into three categories (A, B 
or C) according to the size of the cyst on transvaginal 
ultrasound (0 to 5 cm, 5 to 10 cm and larger than 10 cm). 
Sequentially numbered, opaque, sealed envelopes will be 
used to ensure allocation concealment for the surgeon 
and the outcome assessor. The management assistant will 
safeguard the allocation code until the last visit of the last 
patient. The management assistant will not be involved in 
the outcome assessment or the data collection.
All participating women and the outcome assessor will 
be blinded to the allocation by the use of non-therapeutic 
skin incisions. It is impossible to blind the surgeon. In case 
of life-threatening adverse events, the outcome assessor 
will notify the surgeon to enable further treatment 
without the need for non-blinding the patient. The use of 
the vNOTES technique avoids the use of abdominal inci-
sions. Participants allocated to the vNOTES arm will have 
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three superficial non-therapeutic skin incisions similar 
to those routinely done with the laparoscopic technique. 
This enables blinding all study participants, personnel 
and the outcome assessor. The wound dressings of all 
women will be left untouched until the postoperative visit 
on day 7. The practice of using non-therapeutic skin inci-
sions has been reported in some surgical trials to minimise 
performance and detection bias when measuring subjec-
tive outcomes (eg, pain).23 The decision to use non-thera-
peutic skin incisions is justified by the risk to benefit ratio 
of the two interventions under comparison.24 Its use in 
the HALON and NOTABLE trials has been intensively 
discussed among the investigators. The written approval 
with the Belgian unique study identifier B689201526268 
was sent to the Federal Agency for Medicines and Health 
Products (FAMHP) in Brussels.
statistical methods
Sample size calculation
A sample size calculation was done for the primary 
outcome only. An appropriate level of statistical power was 
applied to preclude any clinically important inferiority of 
vNOTES compared with laparoscopy. The assumptions for 
the sample size calculation are based on evidence retrieved 
from two sources: a randomised study comparing the exci-
sion of mature dermoid cysts using colpotomy with laparo-
scopic assistance versus colpotomy without laparoscopy25 
and an SR with meta-analysis comparing single port lapa-
roscopy versus conventional laparoscopy in benign adnexal 
disease.26 An important consideration in any adnexal mass 
surgery is the inadvertent opening of the ovarian capsule 
of an unsuspected malignancy resulting in the spill of 
malignant cells into the abdominal cavity. Based on a 
2.4% failure rate to remove dermoid cysts by colpotomy 
using laparoscopic assistance25 and a 0% conversion rate 
from laparoscopy to laparotomy,26 we assumed that the 
successful removal of adnexal cysts without spill would be 
feasible in 95% of all cases. The sample size was calculated 
with a one-sided test for non-inferiority for the primary 
outcome. The vNOTES approach may be the treatment of 
choice for women because it avoids scars. We assume that 
vNOTES would be the preferred technique even when 
15% less women had in the end a successful removal of 
a benign adnexal mass by using vNOTES compared with 
laparoscopy with its unavoidable scars. Non-inferiority will 
be concluded when 15% lies above the upper limit of the 
95% CI calculated for the difference in the proportion 
of women successfully treated with either technique. To 
achieve 80% power to demonstrate non-inferiority under 
the assumption of similar success rates of 95% in both 
groups, a sample size of 54 participants (27 women per 
group) will be required. We increased the target sample 
size to 64 participants (32 women per group) to account 
for a dropout rate of 15%. Based on the power calcula-
tions for the primary outcome, the use of three strata for 
the randomisation and assuming a loss-to-follow-up rate 
of 15%, we decided to include 66 study participants in the 
NOTABLE trial.
statistical analyses
General principles
For all baseline and outcome variables, the number 
of available measurements and the number of missing 
values will be given. A probability (P) less than 0.05 
will be considered to be significant. Analysis will be 
performed by intention-to-treat, as recommended 
in the Consolidated Standards of Reporting Trials 
(CONSORT) statement.27 Since the study compares two 
regular interventions and is expected to recruit during 
a reasonably limited period, interim analyses will not be 
performed.
Categorical data will be reported as absolute numbers 
and percentages. Normally distributed continuous vari-
ables will be summarised as means with SDs, and non-nor-
mally distributed continuous variables will be reported as 
medians with IQR. Main analyses will not impute missing 
values.
All analyses will be performed using SAS software (V.9.4 
of the SAS System for Windows).
dEsCrIPtIvE AnAlysEs
study population—baseline characteristics
 ► Mean age (±SD),
 ► Mean body mass index (BMI) (±SD),
 ► Mean number of natural vaginal births (±SD),
 ► Mean number of abdominal/pelvic surgical interven-
tions (±SD),
 ► Mean weight of the uterus (±SD).
study EndPoInts
Main study parameter/endpoint
Differences in the proportions of women successfully 
treated by removing the uterus by the intended technique 
without conversion to another approach.
secondary study parameters/endpoints
 ► Proportions of women hospitalised on the day of 
surgery;
 ► Postoperative pain scores, measured using VAS two 
times per day from day 1 to 7 self-reported by the 
study participants;
 ► Total dose analgesics used during the first week 
following surgery;
 ► Incidence of postoperative infection during the first 
6 weeks of surgery;
 ► Incidence of intraoperative complications;
 ► Incidence of postoperative complications during the 
first 6 weeks following surgery;
 ► Incidence of readmission during the first 6 weeks of 
surgery; 
 ► Incidence of dyspareunia recorded by the participants 
at baseline, 3 and 6 months by self-reporting using a 
simple questionnaire;
 ► Severity of dyspareunia recorded by the participants at 
baseline, 3 and 6 months by self-reporting using VAS;
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 ► Sexual well-being at baseline, 3 and 6 months by self-re-
porting the SSFS QoL at baseline, 3 and 6 months by 
self-reporting the EQ-5D-3L questionnaire;
 ► Duration of surgery;
 ► Total costs of both intervention surgeries.
stAtIstICAl AnAlysIs
For the primary outcome measure, a one-sided 95% CI 
of the difference in the proportions of women with a 
successful removal of the uterus by the intended tech-
nique as randomised will be estimated. Non-inferiority 
will be concluded when 15% lies above the upper limit 
of this 95% CI.
For the manuscript, all above listed secondary outcomes 
will be compared between the two groups. These data will 
be reported as vNOTES versus laparoscopy.
For dichotomous secondary outcome measures, 
comparisons between the two arms will be performed by 
applying Fisher’s exact test or Χ2 test, as appropriate.
Cross-sectionally measured continuous secondary 
outcomes will be analysed using an independent t-test or 
Mann–Whitney U test, as appropriate.
Longitudinally measured continuous secondary 
outcomes will be analysed using multilevel modelling. 
Differences in evolution between both treatment groups 
will be compared by means of a time by group interaction. 
In absence of such an interaction, mean differences will 
be compared over all time points. Outcome scores will be 
transformed if required to meet model assumptions.
All statistical analyses will be done by an experi-
enced biostatistician (AL) who is a coinvestigator. After 
data cleaning, the management secretary will send the 
non-blinded data to the biostatistician after the last visit of 
the last patient. The biostatistician will do all the analyses 
without any assistance of the other investigators who will 
remain blinded until all data have been analysed.
The following strategy will be used in case of missing 
data. In case of a single item response missing, the data 
will be imputed from given values. In cases where more 
than one item is missing or an entire form is missing, 
imputation will not be attempted. We will assess whether 
the obtained results are robust to the methods used to 
handle missing data, by performing a sensitivity analysis.
MonItorIng
NOTABLE is a small trial; therefore, a data monitoring 
committee is not needed.
All adverse events reported spontaneously by the partic-
ipant or observed by the investigator or his staff will be 
recorded. Infection and perioperative or postoperative 
complications will be assessed as secondary outcomes 
until 6 weeks after surgery. We will inform the family physi-
cian of all participants in order to assess all possible unin-
tended effects of the trial intervention and promote to 
report all possible adverse events anonymously using the 
participant’s unique study number to an email address ( 
NOTES@ imelda. be). We will use descriptive statistics for 
data analysis although the trial is not adequately powered 
to detect important differences in rates of uncommon 
adverse events. Given the limited resources and the single-
centre design, there will be no auditing of the conduct of 
the trial. We will review patient enrolment, consent and 
eligibility on a regular basis to promote data quality and 
to preserve trial integrity. The distribution of the alloca-
tion to the study groups will be blindly checked by the 
study secretary at 30%, 60% and 90% of the recruitment 
and discussed with the study statistician and the principal 
investigators.
rEsults
Participant flow diagram
Figure 1 shows the study flow reported as outlined by the 
CONSORT (figure 1).
recruitment time frame
All potentially eligible women aged 18 to 70 years, regard-
less of parity, in need of adnexal surgery for benign 
gynaecological disease without exclusion criteria will be 
invited to participate in the trial. Only eligible women 
with written informed consent obtained before randomi-
sation will be finally included in the NOTABLE trial.
We perform 36 interventions for adnexal surgery by lapa-
roscopy for benign gynaecological disease at our Depart-
ment of Gynaecology per year. The recruitment period of 
NOTABLE to meet the sample size will be approximately 
2 years. Including the follow-up period of 6 months after 
the last patient last visit and the time required to perform 
data analysis and reporting (6 months to 1 year), we esti-
mate that the total study period will be at least 3 years.
data collection
We will record the following patient characteristics at 
baseline: age, BMI, the number of vaginal births, previous 
abdominal or pelvic surgery (C sections included), 
adnexal size, concomitant medication, dyspareunia ques-
tionnaire and the SSFS.
On the day of surgical intervention (day 0), we will 
record the following data: the duration of the surgical 
intervention, the successful removal of the adnexa by 
the technique as allocated without conversion to another 
technique with or without spilling (into the peritoneal 
cavity or the endobag), hospitalisation of the participant 
on the day of the surgical intervention based on her own 
preference, the total dosage of analgesics used at the 
recovery and day care unit and the maximum VAS pain 
score on the day 0.
After 1 week at visit day 7, the outcome assessor will 
collect the pain scores as self-reported by the study partic-
ipants two times per day from day 1 to day 7 using VAS. 
The outcome assessor will also collect data on the total 
dosage of pain killers used during the first postoperative 
week.
At visit day 7 and day 42, the outcome assessor will 
record the following data: pelvic infection defined by 
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lower abdominal pain with fever >38°C and positive clin-
ical signs or laboratory findings, readmission to hospital 
and the occurrence of other postoperative complications 
classified according to the Clavien-Dindo classification.
On months 3 and 6 following surgery, the dyspareunia 
questionnaires, the EQ-5D-3L and the SSFS question-
naires will be filled in by the study participants and 
collected by regular mail. The management assistant will 
oversee this process and send reminders until all ques-
tionnaires have been received. We refer to table 1 for an 
overview of the data collection process (table 1).
dIsCussIon
Interpretation, limitations and generalisability
The NOTABLE trial is a randomised pilot study on the 
efficacy of the vNOTES technique. All surgical proce-
dures in the NOTABLE study are done by one single 
surgeon (JFB) who is equally skilled in using both tech-
niques under comparison. The surgeon has been using 
the vNOTES approach since November 2013. During 
this 2-year period, the new technique and suitable instru-
ments used were pilot-tested and subsequently fine-tuned 
by the usual ‘trial and error’ method used for centuries in 
surgical practice.17 The feasibility and preliminary safety 
of the new technique were reported in three observational 
studies performed at our department9–11 in accordance 
with the principles outlined in the three article series on 
the IDEAL statement.15–17 According to the terminology 
used by the IDEAL collaboration,17 this study should be 
classified as an IDEAL stage 2b trial. The full Patient Inter-
vention Control Outcome (PICO) research question is as 
follows: will a surgeon who is equally skilled at performing 
both techniques, and beyond his learning curve for the 
new technique (vNOTES), succeed in removing one 
or both adnexa in women with benign gynaecological 
disease at least as often with the new pilot-tested vNOTES 
approach compared with the standard transabdominal 
laparoscopic approach without having to convert to any 
other technique. An intraoperative decision to remove 
an adnexa via laparoscopy and not via vNOTES due to, 
for example, a large specimen or an atrophic vagina may 
better be defined as a pre-emptive conversion, as it has 
less clinical implications than a conversion from laparos-
copy to laparotomy. However, for the sake of unambiguity 
in this trial, we decided to count as a conversion every case 
that was not treated by the allocated technique, whether 
the conversion was pre-emptive or not.
NOTABLE aims to measure efficacy of vNOTES for 
removing one or both adnexa (Can vNOTES work under 
ideal experimental conditions?). The NOTABLE trial 
Figure 1 CONSORT (Consolidated Standards of Reporting Trials) 2010 flow diagram. vNOTES, transvaginal natural orifice 
transluminal endoscopic surgery.
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does not address the effectiveness of the new interven-
tion at this moment (Does vNOTES work in a real-life 
setting?). The conditions in NOTABLE are truly exper-
imental and in many instances opposed to ‘real life’ 
practice: all women are always treated by the most expe-
rienced surgeon equally skilled in using both techniques, 
all women receive more attention during this trial than 
the routine care given during standard clinical practice, 
the dosage of anaesthetic drugs is calculated to limit any 
side effect (nausea and vomiting) that may cause women 
to be hospitalised on the day of the surgical interven-
tion, all outcomes measured are very relevant for women 
in general and participants with adverse outcomes (eg, 
dyspareunia and sexual dysfunction) will be recalled after 
the end of the study for counselling and therapy. The 
results of the NOTABLE trial will therefore have a limited 
generalisability, and their interpretation will be done 
cautiously. The testing of the safety and the cost-effective-
ness will be needed in the longer term using pragmatic 
multicentre randomised controlled trials or a prospective 
register.
As suggested by the IDEAL collaboration, more research 
(large multicentre trials performed by adequately trained 
surgeons in centres of clinical excellence and large 
prospective registries cumulating data on the safety of the 
new technique over many years) and adequate surgical 
training will be needed before vNOTES can be offered 
as a standard daily care surgical practice by a majority of 
gynaecological surgeons for all women bound to undergo 
removal of one or both adnexa for benign gynaecological 
disease.
EthICs And dIssEMInAtIon
The NOTABLE trial will be conducted in accordance with 
the ethical principles outlined in the latest version of the 
‘Declaration of Helsinki’, the ‘Guideline for Good Clin-
ical Practice’ and the Belgian Law of 7 May 2004 related 
to experiments on humans.
All eligible women wishing to participate in the study 
will receive a detailed patient information document 
about the study protocol, the aims of the research and 
the possible adverse events related to the surgical tech-
niques. We will request written informed consent from all 
participants before randomisation. The principal investi-
gator (JFB) and the coordinating investigator (JJAB) will 
obtain these consents during a study intake. An adapted 
informed consent form (online supplementary appendix 
1) was drafted based on the template proposed by the 
FAMHP for clinical research in Belgium.28
The protocol of the NOTABLE trial is registered in  Clin-
icalTrials. gov of the US National Institutes of Health as 
NCT02630329 (online supplementary appendix 2). The 
study protocol (online supplementary appendix 3) and 
the informed consent documents have been approved by 
the Ethics Committee of the Imelda Hospital, Bonheiden, 
Belgium. The written approval with the Belgian unique 
study identifier B689201526268 was sent to the FAMHP 
Table 1 Patient’s characteristics and data collection
Data collection
Days
BL 0 1 2 3 4 5 6 7 42 3 months 6 months 
Age X 
BMI X 
Uterine volume X 
Concomitant medication X X X X X X X X X X 
Dyspareunia: frequency and intensity X X X 
SSFS X X X 
Health-related quality of life X X X 
Duration of surgery X 
Successful removal X 
Admission in hospital
(for at least one night)
X 
Total amount of analgesics used X X X X X X X X 
VAS score X X X X X X X X 
Readmission within 6 weeks X
Pelvic infection X X
Other postoperative complications X X X
Direct and indirect costs
(up to 6 weeks after surgery)
X
BL, baseline; BMI, body mass index; SSFS, Short Sexual Functioning Scale; VAS, Visual Analogue Scale.
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in Brussels. All substantial protocol modifications will 
be communicated to all trial participants, the hospital’s 
Ethics Committee,  ClinicalTrials. gov and the FAMHP.
The NOTABLE trial is a non-commercial and investi-
gator-driven study. The investigators have taken out an 
insurance policy for medicolegal responsibility related 
with the conduct of the study from 1 December 2015 to 
30 May 2018 in accordance with Article 29 of the Belgian 
Law of 7 May 2014 related to experiments on humans.
The clinical research forms and all other study-re-
lated documents will be stored securely at the study site 
in locked file cabinets in an area with limited access. All 
records that contain names or other personal identifiers 
will be stored separately from study records identified 
by a code number. Data collection, storage and dissem-
ination will be in accordance with the Belgian Law of 8 
December 1992 on the protection of privacy in relation 
to the processing of personal data and by the Law of 22 
August 2002 on patient rights.
At the end of the NOTABLE trial, the complete final 
data set will be accessible to all trial investigators (the 
nine authors of the study protocol).
Offering the surgical intervention identified as being 
most effective or most advantageous after the final anal-
ysis of the study data to those women who were allocated 
to the least effective technique is by nature of the surgical 
intervention not always possible except for women who 
had a unilateral surgical intervention. As part of good 
clinical practice, we will offer post-trial care to women 
with identified adverse events.
The investigators declare that they have no conflict of 
interest with respect to the present research.
The NOTABLE trial results will in all circumstances be 
disseminated through scientific journals and at scientific 
conference presentations regardless of any positive or 
negative outcome in relation with the predefined study 
hypothesis is refuted by the data. All trial investigators 
will contribute to authorship, following the International 
Committee of Medical Journal Editors’s authorship eligi-
bility guidelines.
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